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Abstract
Background: Immunoglobulin G4-related disease (IgG4-rd) is characterized by lymphoplasmacytic infiltration and
tissue fibrosis. Orbital manifestations of IgG4-rd may include unilateral or bilateral proptosis, cicatricial extraocular
muscle myopathy, orbital inflammation and pain which may mimic ophthalmic Graves’ disease.
Case presentation: A 25-year-old woman has been referred to the endocrinology clinic, 4 months after delivery, with
suspected Graves’ orbitopathy. She has had bronchial asthma and recurrent skin rashes of unknown aetiology for the
last 10 years and was treated for dacryoadenitis with steroid containing eye drops 5 years ago. During pregnancy she
developed eyelid swelling. After delivery, eyelid redness and retrobulbar pain evolved. Proptosis was demonstrated by
Hertel’s exophthalmometry. Orbital magnetic resonance imaging showed enlarged lateral and superior rectus muscles
in both orbits. Thyroid function tests were in the normal range and no thyroid stimulating hormone (TSH) receptor
autoantibodies were present. The eye muscle involvement pattern raised suspicion, and the high IgG4 level with
positive histology of the lacrimal gland confirmed the diagnosis of immunoglobulin G4-related orbitopathy. Rapid
improvement was observed following oral methylprednisolone.
Conclusions: IgG4-related orbitopathy may mimic Graves’ orbitopathy. Euthyroid patients with no TSH receptor
autoantibodies should be evaluated for immunoglobulin G4-related orbitopathy. Once IgG4-related orbitopathy is
proven, other manifestations of IgG4-related disease have to be searched for; lifelong follow-up is warranted.
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Background
The most common orbital disease usually with
exophthalmos is Graves’ orbitopathy, which is the extra-
thyroidal complication of Graves’ thyroid disease [1]. The
annual incidence rate of Graves’ orbitopathy has been
estimated at 16 cases per 100,000 women and 2.9 cases
per 100,000 men in one rural Minnesota community [2].
Graves’ orbitopathy usually appears simultaneously with
or soon after the development of thyrotoxicosis; however,
rarely it may precede hyperthyroidism. The most common
clinical features of Graves’ orbitopathy are upper eyelid
retraction, oedema, and erythema of the periorbital tissues
and conjunctivae, proptosis, dry ocular sensation,
photophobia, double vision, and pressure sensation
behind the eyes.
Beside detailed ophthalmological examination (best-
corrected visual acuity, color vision, pupillary examin-
ation, ocular motility, Hertel’s exophthalmometry,
intraocular pressure, adnexal examination, slit-lamp
examination, dilated fundus examination) laboratory
parameters that are necessary to confirm the diagnosis
include: measurement of serum thyroid stimulating
hormone, free thyroxin, and TSH receptor antibody
levels. In euthyreoid Graves’ orbitopathy, TSH receptor
antibody level is elevated without thyroid function
abnormality. The diagnosis of Graves’ orbitopathy in
most patients is obvious; however, exophthalmos can
also be present in patients with lymphoproliferative
disorders of the orbits, idiopathic orbital inflammatory
syndrome, orbital myositis, severe obesity, Cushing’s
syndrome, histiocytosis, granulomatosis with polyangitis,
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and IgG4-related orbitopathy [1, 3, 4]. Orbital magnetic
resonance imaging, orbital computed tomography and/
or single photon emission computed tomography can
help to distinguish between the underlying causes [5–8].
Case presentation
A 25-year-old woman presented in the endocrinology
clinic, in October 2013, with eyelid swelling, redness and
retrobulbar pain with suspected Graves’ orbitopathy after
ophthalmological examination, 4 months after delivery
(Fig. 1). Symptoms started during the third trimester of
her pregnancy, in April 2013, which were considered
pregnancy related phenomena and thus remained un-
treated. The patient did not have diplopia at the first visit,
however, she complained about intermittent double vision
starting 1 month later. In addition, she complained of a
palpable “nodule” in the left side of her face.
The patient has had bronchial asthma and recurrent
skin rashes of unknown aetiology for the past 10 years.
Repeated examinations failed to find any evidence of an
autoimmune disorder. Total IgG level was normal, while
IgA and IgM were lower in 2008; with follow-up being
recommended (Table 1). Dacryoadenitis was diagnosed
by ophthalmological examination and MRI in 2009
(Fig. 2a). Her symptoms disappeared within a few days
after using a steroid containing eye drops.
On arrival at the endocrine unit in 2013, no signs or
symptoms of hyperthyroidism were present. The thyroid
gland was of normal size and without nodules. The palp-
able nodule on her face was identified, by ultrasound, as
an unusual swollen limb of the left parotid gland, while
thyroid ultrasound revealed no abnormalities. Physical
examination revealed rashes on her legs. Proptosis values
(measured by Hertel’s exophthalmometer) were 24 mm
on the right side, and 21 mm on the left side. Visual
acuity was 1.0 in both eyes, intraocular pressures were
16 mmHg and 20 mmHg on the right and left sides, re-
spectively. Pupils were isocoric, equal and had normal
reaction. Digital retropulsion did not suggest a mass or
tumor in the retrobulbar space. Upon examination both
the lower and upper eyelids were found to be markedly
swollen and a swollen lacrimal gland became visible after
the right upper eyelid had been lifted.
Orbital MRI showed enlarged lateral and superior
rectus muscles, and eyelid oedema and swollen lacrimal
gland in both orbits while the typical MRI features of
Graves’ orbitopathy (proptosis, enlarged extraocular
muscles, most frequently the inferior and medial rec-
tuses, excessive amount of orbital connective tissue)
were missing (Fig. 2b, c). Serum levels of TSH and thy-
roid hormones were in the normal range. TSH receptor
antibody and thyroid peroxidase antibody levels were
not elevated (Table 1). Based on her medical history,
laboratory and imaging results, the possibility of IgG4-rd
was suspected. A markedly elevated IgG4 level was
observed (Table 1). Histological examination of the right
lacrimal gland confirmed the diagnosis of Ig4-related
orbitopathy, with both CD138 (the unique cell surface
marker of plasma cells) and IgG4 immunohistochemical
stainings showing plasmacytic infiltration in the same
localisation (Fig. 3), and excluding other IgG4 positive
conditions thereby confirming the diagnosis of IgG4-
related orbitopathy.
Placed on oral corticosteroid administration (methyl-
prednisolone, 16 mg daily) a rapid improvement in both
the eye symptoms and skin rashes was observed within a
few days (Fig. 1). However, after gradual tapering of the
corticosteroid therapy (from January to March 2014),
her ocular symptoms relapsed. After a second course of
oral methylprednisolone for 8 weeks (from April to June
2014), the parotid gland enlargement disappeared and
she remained asymptomatic for the next 24 months.
However, IgG4 level started to rise during follow-up and
in April 2017, periodic skin rashes appeared on the legs.
As IgG4 level rose, skin biopsy was suggested, which she
did not consent to. Her skin symptoms are currently
under control with glucocorticoid-containing ointments.
Should systemic treatment for the IgG4-rd be necessary
in the future, rituximab therapy could be considered,
since she has already rejected any future steroid courses
fearing weight gain as one of its side effects [9]. We as-
sume that the swollen parotid gland and skin symptoms
are additional manifestations of IgG4-rd, however, with-
out biopsy this remains unproven.
Conclusions
IgG4-rd is a recently described and increasingly recog-
nized entity [10] which may present with involvement of
Fig. 1 Changes in the condition of the eyes after 6 days oral
glucocorticoid treatment
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the eyes, termed IgG4-related orbitopathy [4, 11]. IgG4-
rd usually affects more than one organ, typically the
orbits, salivary glands, lungs, pancreas, biliary ducts and
retroperitoneal tissue. Orbital involvement most fre-
quently includes the lacrimal glands and extraocular
muscles, however, infraorbital and supraorbital nerve
enlargement may also be detected [12]. In a series of
1014 orbital lymphoproliferative disease cases, the
incidence of IgG4-related orbitopathy was found to be
21.6% [13]. Features of IgG4-rd include tumor-like swell-
ing of involved organs, lymphoplasmacytic tissue infiltra-
tion enriched in IgG4-positive plasma cells, storiform
fibrosis and obliterative phlebitis [4, 10, 11]. The number
of IgG4-positive plasma cells per high-power field (HPF)
that is regarded as consistent with or suggestive of IgG4-
rd varies somewhat from tissue to tissue. Generally, the
minimum for making the diagnosis for most tissues is
from 30 to 50 IgG4-positive cells/HPF. However, in the
lacrimal gland, 10 IgG4-positive plasma cells/HPF may
be sufficient for the diagnosis [13–15]. Storiform fibrosis
and obliterative phlebitis are more typical of the
systemic pathology; however, they are not always present
in the orbital disease. A specific autoantigenic target has
not been identified; furthermore, it is not clear whether
the IgG4 antibodies are pathogenic. In 2009, diagnostic
criteria for IgG4-rd were proposed, and comprehensive
diagnostic criteria are currently in use [15, 16]. In
patients with typical clinical features and organ involve-
ments both measurement of serum IgG4 levels and tis-
sue biopsy are recommended [14–16]. Elevated serum
concentrations of IgG4 are found in 60–70% of patients
with IgG4-rd, but this finding is not specific, as it can
also be associated with Churg-Strauss syndrome, sar-
coidosis and allergic diseases [17].
All patients with symptomatic active IgG4-rd require
treatment. Glucocorticoids are the first-line agents for
remission induction. Following a successful course of in-
duction therapy, certain patients benefit from mainten-
ance therapy. Repeated glucocorticoid courses are
indicated in patients who relapse following successful re-
mission induction. Most patients respond to glucocorti-
coids within several weeks, typically with symptomatic
Table 1 Relevant laboratory values. Glucocorticoids were administered from January to March and from April to June, 2014
Laboratory parameters (with normal ranges) May 2008 October 2013 January 2014 May 2014 July 2014 July 2015 June 2016 April 2017
TSH (0.3–4.2 mU/L) 1.25 3.36 1.72 2.02 2.1 2.17 2.62 2.23
free T4 (12–22 pmol/L) 13.7 14.6 14.8 13.4 15 15.2 13.4 14.2
free T3 (2.4–6.3 pmol/L) 4.4 5.1 4.9 4.9 4.1 5.2 5.1 4.6
TSH receptor antibody
(<1 U/L, 1–2: grey zone)
– 1.0 <1 <1 – <1 <1 <1
thyroid peroxidase antibody
(<60 IU/ml)
<30 <30 <30 <30 – <30 – –
IgG4 (0.08–1.4 g/L) – – 9.4 3.03 1.29 10.5 14.9 12.6.
IgG (6.9–14 g/L) 12.31 – 9.9 4.87 5.5 10.9 12.9 12.8
IgM (0.4–2.4 g/L) 0.25 – 0.3 0.74 0.58 0.4 0.43 0.46
IgA (0.7–3.7 g/L) 0.61 – 0.5 0.63 0.6 0.6 0.65 0.5
a b c
Fig. 2 MRI of the orbits. a: T2 axial scan (in 2009). Inflammation in the right lacrimal gland and in surrounding connective tissue (arrow). b: T1
coronal scan (in 2013). The lateral and superior rectus muscles are enlarged in both orbits (arrows). c: T2 axial scan (in 2013). The arrow points to
swollen lacrimal gland in the right orbit
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improvement, reduction in the size of masses or en-
larged organs, improvement in organ function, and a de-
crease in serum levels of IgG4 [4]. However, some
require a few months to respond, while others relapse
and others who respond less well or not at all initially.
In those who are resistant to glucocorticoids, or have
side effects or contraindications to glucocorticoid ther-
apy, rituximab is another therapeutic option [9].
Neither the natural course nor the prognosis of IgG4-
rd is well-understood. Spontaneous improvements can
be seen, but the disease often relapses if left untreated.
Symptoms respond dramatically to glucocorticoids, but
relapses are common following discontinuation of ther-
apy. Significant organ dysfunction may arise from
uncontrolled and progressive inflammatory and fibrotic
changes in affected tissues. Currently, it is uncertain if
there is an increased risk of malignancy in patients with
IgG4-rd, however, lymphomas occur more frequently in
patients with IgG4-related disease [10, 16].
The prevalence of the disease could be more frequent
than it is diagnosed [13]. There is enhanced attention
towards IgG4-related orbitopathy in Japan [4, 13], as
well as few published cases in Europe.
As far as clinical manifestations are concerned, cutane-
ous presentations, similar to the present case, may be
the first sign of IgG4-rd [18].
The most typical manifestations of IgG4-related orbi-
topathy are the usually easily detectable dacryoadenitis,
swollen eyelid and involvement of extraocular muscles.
The external eye muscle involvement pattern on MRI is
distinct from Graves’ orbitopathy, where the inferior and
medial rectuses are the most frequently involved
muscles [5]. In IgG4-related orbitopathy these muscles
are often spared, as seen in our case (Fig. 2b) [12]. Less
commonly, compressive optic neuropathy secondary to
mass effect from inflammatory lesions may result in
visual loss, afferent pupillary defect, or visual field
defects. Mass effect can particularly occur in patients
with infraorbital nerve enlargement, which is defined as
the infraorbital nerve being greater in diameter than the
optic nerve. Infraorbital nerve enlargement is signifi-
cantly correlated with elevated serum IgG4 levels.
Sensory loss is extremely rare. Other less common mani-
festations are frontal nerve and perioptic nerve lesions.
Involvement of the nasolacrimal duct system can cause
epiphora. In rare cases of IgG4-related orbitopathy caus-
ing scleritis, patients may present with conjunctival and
scleral injection with blurred vision [18].
In our patient, skin symptoms and salivary gland
enlargement have also been components of IgG4-rd.
Although only the lacrimal gland was biopsied, improve-
ment of the skin and salivary gland lesions after
glucicorticoid therapy was indirect evidence of the
involvement of these organs. Symptoms which were typ-
ical of bronchial asthma may have been caused by IgG4-
rd. Possible pulmonary manifestations of this condition
are nonspecific interstitial pneumonia, sclerosing
mediastinitis, mediastinal or hilar adenopathy, massive
pleural effusion, nodular pleural lesions and pulmonary
arterial hypertension [19, 20]. During follow-up, we did
not detect any of these abnormalities.
The case presented here is rather unique as the patient
is a young woman, since IgG4-rd occurs predominantly
in elderly men [11, 12]. In her case age would have been
rather characteristic of Graves’ orbitopathy. Data on the
association of IgG4-rd and Hashimoto’s or Riedel’s thy-
roiditis exist [21], but similar association with Graves’
disease has not been described. Notably, one group
found elevated IgG4 levels in 6.4% of 109 patients with
Graves’ disease. This subgroup of patients was signifi-
cantly older, their symptoms were manageable with
small doses of antithyroidal drugs and they were prone
to be hypothyroid after treatment [22]. It has recently
been shown that IgG4 levels may be elevated in newly
a b c
Fig. 3 Histology of the lacrimal gland. a: Haematoxylin and Eosin staining. There is lymphoplasmacytic infiltration dominantly in the middle of
the picture (arrow). b: CD138 immunostaining. Plasma cells are brown (arrow). c: IgG4 immunostaining. IgG4-positive plasma cells brown (arrow)
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diagnosed Graves’ disease patients compared with
euthyroid subjects and in the presence of Graves’ orbito-
pathy compared with the absence of Graves’ orbitopathy
[23]. However, the IgG4 rise in IgG4-rd is more marked.
Corticosteroid treatment is the standard therapeutic op-
tion for both Graves’ orbitopathy and IgG4-related orbi-
topathy, but unlike in Graves’ orbitopathy, marked
response to low corticosteroid doses is typical in IgG4-
related orbitopathy [4].
IgG4-related orbitopathy may easily be mistaken for
Graves’ orbitopathy [24]. All patients with suspected
euthyroid Graves’ orbitopathy in whom TSH receptor
autoantibodies are not present have to be evaluated for
IgG4-related orbitopathy. Once IgG4-related orbitopathy
is proven, other manifestations of IgG4-rd have to be
searched for; lifelong follow up is required. Immuno-
globulin G4-related disease is an increasingly recognized
syndrome of unknown etiology. IgG4-rd could affect
many organs and tumor-like swelling of the involved
organs is common. Several of the manifestations typic-
ally occur in the same patient. The diagnosis of IgG4-rd
is based upon biopsy findings (IgG4 positive lympho-
plasmacytic infiltration and tissue fibrosis). Serum IgG4
level should be measured, and isolated elevated levels
support the diagnosis, although it is not fully diagnostic
without histological examination. Due to various
manifestations of this new entity, a multidisciplinary
approach is warranted.
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